Catherine C. Coombs, MD, The University of North Carolina Cancer Center, Chapel Hill, NC, discusses long-term management of chronic lymphocytic leukemia (CLL) to improve patient outcomes. With emergent novel targeted therapies like Bruton’s tyrosine kinase inhibitors (BTKi), the treatment paradigm has now shifted away from the historic mainstay of intensive chemotherapy. Dr Coombs also talks of time-limited non-cytotoxic approaches such as venetoclax which is increasingly being seen in the front-line and relapsed/refractory setting in combination with other novel agents. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Catherine C. Coombs, MD, has received honoraria or participated in consultancy work for AbbVie, Genentech, AstraZeneca, LOXO, Novartis and MEI Pharma; and has received institutional funding from AbbVie, LOXO, Incyte and h3 biomedicine.